Effects of DPP-4 inhibitors, GLP-1 receptor agonists, SGLT-2 inhibitors, and sulfonylureas on mortality, cardiovascular and renal outcomes in type 2 diabetes: a network meta-analyses-driven approach.
Andreas BrøndenMikkel Bring ChristensenDorte GlintborgOle SnorgaardAllan Kofoed-EnevoldsenGitte Krogh MadsenKatja ToftJette Kolding KristensenKurt HøjlundTroels Krarup HansenEsben SøndergaardKatrine Bagge HansenPublished in: Diabetic medicine : a journal of the British Diabetic Association (2023)
The findings from our analyses substantiate the relevance of treatment with SGLT-2 inhibitors or GLP-1RAs as add-on to metformin in patients with T2D and a high risk for cardiovascular disease, and furthermore, support the recommendation for SGLT-2 inhibitor treatment in patients with T2D and heart failure or established kidney disease.